Immunocore: Pipeline Expands HLA Tumor Targeting Beyond Kimmtrak [Seeking Alpha]
Immunocore Holdings plc - American Depositary Shares (IMCR)
Company Research
Source: Seeking Alpha
Follow Summary In Q2 of 2024, sales of Kimmtrak were $75 million, which was a year-over-year increase of 32%. Two expansion opportunities are possible for Kimmtrak, which are using it as an adjuvant for uveal melanoma and 2nd-line advanced cutaneous melanoma. Data from the phase 1/2 study, using brenetafusp for the treatment of patients with high-grade serous ovarian cancer, to be presented as a poster at the upcoming ESMO 2024 conference. Data from the phase 1/2 study, using brenetafusp for the treatment of patients with late-line non-small cell lung cancer to be presented at a medical conference in Q4 of 2024. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » Bevan Goldswain/E+ via Getty Images Immunocore NASDAQ: IMCR ) has made significant progress in being able to use its proprietary ImmTAX platform to develop T-cell receptors [TCRs] against a variety of types of
Show less
Read more
Impact Snapshot
Event Time:
IMCR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMCR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMCR alerts
High impacting Immunocore Holdings plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IMCR
News
- FATE Presents Encourgaing Data From Lupus Study, Stock Gains [Yahoo! Finance]Yahoo! Finance
- Immunocore Holdings plc (IMCR): This Small-Cap Stock Is Ready To Explode [Yahoo! Finance]Yahoo! Finance
- FATE Q3 Earnings Beat on Higher Revenues, Pipeline in Focus [Yahoo! Finance]Yahoo! Finance
- Immunocore Holdings plc (NASDAQ: IMCR) was downgraded by analysts at Mizuho from an "outperform" rating to a "neutral" rating. They now have a $38.00 price target on the stock, down previously from $72.00.MarketBeat
- The Galien Foundation Honors 2024 Prix Galien Award RecipientsPR Newswire
IMCR
Earnings
- 11/6/24 - Beat
IMCR
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- IMCR's page on the SEC website